Anticoagulant therapy for deep venous thrombosis of the upper extremity in 33 patients was associated with a more favorable prognosis than historically expected.
Observational (n=33)
THROMBOSIS of the axillary and subclavian veins is a rare entity. In the statistical compilation by Barker et al of thromboembolic disease seen at the Mayo Clinic,1thrombosis of deep veins of the upper extremity represented only 1.7% of 1,260 cases. In a recent assessment by us of 2,400 episodes of deep venous thrombosis recognized over a 15-year interval, thrombosis of deep veins of the arm constituted 1.3% of the total. The largest single group of cases we have encountered in the medical literature is a series of 46 patients reported by Veal and Hussey in 19432; these individuals received no specific therapy. During the course of summarizing the results of anticoagulant therapy of deep venous thrombosis at our institution, we were impressed with a prognosis more favorable than expected2,3in 33 patients with deep venous thrombosis of the upper extremity who received anticoagulants for treatment of
William W. Coon (Mon,) conducted a observational in Thrombosis of axillary and subclavian veins (n=33). Anticoagulants was evaluated. Anticoagulant therapy for deep venous thrombosis of the upper extremity in 33 patients was associated with a more favorable prognosis than historically expected.